Aditxt Inc (ADTX)

$0.00 -0.01 (-75.79%)
Market Cap 8,000.00
Revenue (ttm) 3,195.00
Net Income (ttm) -41.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 362,990,313
Avg Vol 302,860,438
Day's Range N/A - N/A
Shares Out 816,000.00
Stochastic %K 0%
Beta 0.84
Analysts Strong Buy
Price Target $61.00

Company Profile

Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It develops ADI-100 for skin grafting, psoriasis, and type-1...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 870 1200
Address:
2569 Wyandotte Street, Suite 101, Mountain View, United States
ShootsLeft87
ShootsLeft87 Jul. 4 at 6:11 PM
$ADTX Its already July ! That leaves August .Then September!💥 Buying up sub penny dips this week. I slapped the ask on my last buy. What an honour it’s been to be on this ride with you Bulls
0 · Reply
TradeForLifeKing
TradeForLifeKing Jul. 4 at 3:17 PM
$ADTX trend is speaking up for itself... weekly amazing and to continue.....
0 · Reply
trt102967
trt102967 Jul. 4 at 3:10 PM
$ADTX
0 · Reply
TradeForLifeKing
TradeForLifeKing Jul. 4 at 3:03 PM
$ADTX No wonder why they loading shares, this is going to recover most likely everyone, let’s see !!!
0 · Reply
mcclain23theoracle
mcclain23theoracle Jul. 4 at 12:48 PM
$ADTX Christopher Castillo reports 62,000 ADTX shares | ADTX SEC Filing - Form SCHEDULE 13G/A https://www.stocktitan.net/sec-filings/ADTX/schedule-13g-a-aditxt-inc-amended-passive-investment-disclosure-ca8248f9ff59.html
3 · Reply
mcclain23theoracle
mcclain23theoracle Jul. 4 at 12:48 PM
$ADTX Aditxt insider reports 75,000 shares (9.19%) | ADTX SEC Filing - Form SCHEDULE 13G https://share.google/jRS8uXkMeT3KDXIDN
1 · Reply
Lenhhoxung1998
Lenhhoxung1998 Jul. 4 at 12:33 PM
$ADTX its the same fking shit as reverse split stocks to drop offering and dilute to make investor lose money. Its scammer holy shit
2 · Reply
landking1
landking1 Jul. 4 at 11:56 AM
$ADTX I buy through E Trade
1 · Reply
ExplorerX
ExplorerX Jul. 4 at 9:36 AM
$ADTX 👇👇👇
0 · Reply
Innerchild
Innerchild Jul. 4 at 9:20 AM
$GDC Same shit with $ADTX down 99.99%. All these scam tickers, may their gained wealth through deceit and scam be burned with them. disgusting filthy pricks
1 · Reply
Latest News on ADTX
Why Is Penny Stock Aditxt (ADTX) Up Today?

2026-06-18T13:30:09.000Z - 16 days ago

Why Is Penny Stock Aditxt (ADTX) Up Today?

Aditxt signs agreement valuing Ignite Proteomics at $150M

2026-06-09T11:50:09.000Z - 25 days ago

Aditxt signs agreement valuing Ignite Proteomics at $150M

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Jun 9, 2026, 7:45 AM EDT - 25 days ago

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

Jun 8, 2026, 8:15 AM EDT - 26 days ago

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

Aditxt appoints Busch as interim CEO

2026-06-01T15:05:46.000Z - 4 weeks ago

Aditxt appoints Busch as interim CEO

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

Jun 1, 2026, 8:15 AM EDT - 4 weeks ago

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

Aditxt announces 1-for-27 reverse stock split

2026-05-14T16:21:02.000Z - 7 weeks ago

Aditxt announces 1-for-27 reverse stock split

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

May 14, 2026, 8:15 AM EDT - 7 weeks ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

Aditxt announces publication featuring Ignite Proteomics subsidiary

2026-04-20T12:30:43.000Z - 2 months ago

Aditxt announces publication featuring Ignite Proteomics subsidiary

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Apr 20, 2026, 8:15 AM EDT - 2 months ago

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics' RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Aditxt files to sell 148.28M shares of common stock for holders

2026-04-13T10:11:46.000Z - 2 months ago

Aditxt files to sell 148.28M shares of common stock for holders

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Mar 19, 2026, 8:15 AM EDT - 3 months ago

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer

Aditxt acquires Ignite Proteomics in $36M transaction

2026-03-13T12:55:13.000Z - 4 months ago

Aditxt acquires Ignite Proteomics in $36M transaction

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Mar 13, 2026, 8:15 AM EDT - 4 months ago

Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection

Aditxt to effect 1-for-8 reverse split of common stock

2026-03-05T14:03:50.000Z - 4 months ago

Aditxt to effect 1-for-8 reverse split of common stock

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

Mar 5, 2026, 8:30 AM EST - 4 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-8 Reverse Stock Split Effective at the Open of Trading on March 9, 2026

3 Penny Stocks to Watch Now, 12/2/25

2025-12-02T16:19:00.000Z - 7 months ago

3 Penny Stocks to Watch Now, 12/2/25

BEAM KTTA

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Nov 18, 2025, 8:00 AM EST - 8 months ago

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Oct 29, 2025, 4:30 PM EDT - 8 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Aditxt begins enrollment in Mitomic Endometriosis Test study

2025-10-27T13:00:25.000Z - 8 months ago

Aditxt begins enrollment in Mitomic Endometriosis Test study

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Oct 27, 2025, 8:30 AM EDT - 8 months ago

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Evofem Announces Voting Results from Special Meeting of Stockholders

Oct 20, 2025, 4:19 PM EDT - 9 months ago

Evofem Announces Voting Results from Special Meeting of Stockholders

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Sep 11, 2025, 9:18 AM EDT - 10 months ago

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Sep 9, 2025, 9:28 AM EDT - 10 months ago

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Aug 25, 2025, 9:15 AM EDT - 11 months ago

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aug 21, 2025, 8:56 AM EDT - 11 months ago

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Aug 19, 2025, 9:39 AM EDT - 11 months ago

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aug 14, 2025, 8:46 AM EDT - 11 months ago

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Aug 11, 2025, 8:30 AM EDT - 11 months ago

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aug 5, 2025, 8:46 AM EDT - 11 months ago

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Jul 29, 2025, 9:00 AM EDT - 1 year ago

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Jul 24, 2025, 8:15 AM EDT - 1 year ago

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Jul 22, 2025, 8:15 AM EDT - 1 year ago

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Jul 15, 2025, 9:12 AM EDT - 1 year ago

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Jul 7, 2025, 8:15 AM EDT - 1 year ago

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Jun 26, 2025, 8:15 AM EDT - 1 year ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Aditxt files to sell up to 50M shares of common stock for holders

2025-06-20T21:15:06.000Z - 1 year ago

Aditxt files to sell up to 50M shares of common stock for holders

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Jun 11, 2025, 8:14 AM EDT - 1 year ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Aditxt appoints Evofem CEO Saundra Pelletier to board

2025-06-09T12:20:54.000Z - 1 year ago

Aditxt appoints Evofem CEO Saundra Pelletier to board

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 9, 2025, 8:15 AM EDT - 1 year ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Jun 5, 2025, 8:15 AM EDT - 1 year ago

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Aditxt announces termination of arrangement agreement with Appili Therapeutics

2025-05-19T12:11:08.000Z - 1 year ago

Aditxt announces termination of arrangement agreement with Appili Therapeutics

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 19, 2025, 8:00 AM EDT - 1 year ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

May 2, 2025, 9:00 AM EDT - 1 year ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Apr 17, 2025, 8:15 AM EDT - 1 year ago

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Apr 16, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Apr 14, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Apr 11, 2025, 8:15 AM EDT - 1 year ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Apr 9, 2025, 8:15 AM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Apr 2, 2025, 8:15 AM EDT - 1 year ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 28, 2025, 8:15 AM EDT - 1 year ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:30 AM EDT - 1 year ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 24, 2025, 8:15 AM EDT - 1 year ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 17, 2025, 8:15 AM EDT - 1 year ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 12, 2025, 4:15 PM EDT - 1 year ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Mar 6, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 21, 2025, 8:15 AM EST - 1 year ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Feb 13, 2025, 8:15 AM EST - 1 year ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Jan 13, 2025, 8:15 AM EST - 1 year ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Dec 12, 2024, 8:15 AM EST - 1 year ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 14, 2024, 4:36 PM EST - 1 year ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 8, 2024, 8:30 AM EST - 1 year ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

ShootsLeft87
ShootsLeft87 Jul. 4 at 6:11 PM
$ADTX Its already July ! That leaves August .Then September!💥 Buying up sub penny dips this week. I slapped the ask on my last buy. What an honour it’s been to be on this ride with you Bulls
0 · Reply
TradeForLifeKing
TradeForLifeKing Jul. 4 at 3:17 PM
$ADTX trend is speaking up for itself... weekly amazing and to continue.....
0 · Reply
trt102967
trt102967 Jul. 4 at 3:10 PM
$ADTX
0 · Reply
TradeForLifeKing
TradeForLifeKing Jul. 4 at 3:03 PM
$ADTX No wonder why they loading shares, this is going to recover most likely everyone, let’s see !!!
0 · Reply
mcclain23theoracle
mcclain23theoracle Jul. 4 at 12:48 PM
$ADTX Christopher Castillo reports 62,000 ADTX shares | ADTX SEC Filing - Form SCHEDULE 13G/A https://www.stocktitan.net/sec-filings/ADTX/schedule-13g-a-aditxt-inc-amended-passive-investment-disclosure-ca8248f9ff59.html
3 · Reply
mcclain23theoracle
mcclain23theoracle Jul. 4 at 12:48 PM
$ADTX Aditxt insider reports 75,000 shares (9.19%) | ADTX SEC Filing - Form SCHEDULE 13G https://share.google/jRS8uXkMeT3KDXIDN
1 · Reply
Lenhhoxung1998
Lenhhoxung1998 Jul. 4 at 12:33 PM
$ADTX its the same fking shit as reverse split stocks to drop offering and dilute to make investor lose money. Its scammer holy shit
2 · Reply
landking1
landking1 Jul. 4 at 11:56 AM
$ADTX I buy through E Trade
1 · Reply
ExplorerX
ExplorerX Jul. 4 at 9:36 AM
$ADTX 👇👇👇
0 · Reply
Innerchild
Innerchild Jul. 4 at 9:20 AM
$GDC Same shit with $ADTX down 99.99%. All these scam tickers, may their gained wealth through deceit and scam be burned with them. disgusting filthy pricks
1 · Reply
msoykan
msoykan Jul. 4 at 8:16 AM
$ADTX In my estimation , the ADTX company could reach the. 50 $ level. Because it deserves it. l expect it to reach that pount soon...
0 · Reply
Sam75005
Sam75005 Jul. 4 at 7:46 AM
$ADTX which OTC brooker has this stock please? I'm totally lost after being delisted.
1 · Reply
TradeForLifeKing
TradeForLifeKing Jul. 4 at 5:58 AM
$MRNA company should buy instantly $ADTX company that has amazing pipeline everyone for at minimum $10-$20 per share all deal!!!
1 · Reply
marketmakersmarket
marketmakersmarket Jul. 4 at 5:30 AM
$ADTX the reason companies are registered in Delaware is it the state with best shareholder rights. 1. Minority shareholder can take action if they face oppressive conduct which includes UNFAIR dilution of shares . 2. Minority shareholders can challenge decisions made by majority shareholders that adversely affect their interest , including the issuance of new shares that dilute their ownership. Since Trump became President they think they can do whatever they want and ignore the rules and laws.
0 · Reply
JacobTHEJames
JacobTHEJames Jul. 4 at 5:18 AM
$ADTX So everyone was calling me all kinds of names for pointing this out. Last week of you Google searched ADTX and clicked on Robinhood (not logging in or anything) it showed the price of 1.63 with an increased percentage of 70,562.17% So this does add up to the price after the last reverse split. But coincidentally when it first went to OTC the median price 0.0023 and when you multiplied it by that percentage increase you get the same thing. I don't believe in coincidences. Now if you do the same thing it shows the same price but it shows the percentage increase of 32,400%. If you take the current trading median price of what it's trading at which is .0050 and multiply it by 32,400% you get the same price per share of $1.63. If the price listed is because the reverse split why did the percetage increase change? Why does the median of the trading price multiplied by the previous and current median trading price add up?
1 · Reply
marketmakersmarket
marketmakersmarket Jul. 4 at 5:09 AM
$ADTX noticed they ALL resigned? They did not resigned they were fired in a corporate hijacking or faking their resignations line Epstein faked his death and the day Epstein committed suicide the jail camera was not working .. yeah right ..lame excuse
0 · Reply
sullivan1
sullivan1 Jul. 4 at 4:53 AM
$ADTX Aditxt inc management team The current executive management team at Aditxt, Inc. includes: Jeffrey M. Busch: Interim Chief Executive Officer (and CEO of Ignite Proteomics, an Aditxt subsidiary). Thomas J. Farley: Chief Financial Officer. Dr. Shahrokh Shabahang: Co-founder and Chief Innovation Officer. Corinne Pankovcin: Chief Mergers & Acquisitions (M&A) Officer. Jennifer Lee: Director of Human Resources.
1 · Reply
marketmakersmarket
marketmakersmarket Jul. 4 at 4:52 AM
$ADTX Amro Alanna ,the CEO resigned on May 31 ,2026 The Chief Financial Officer resigned on June 2,206 Christopher Porcelli resigned as General Counsel on June 2, 2026 The chairman of the board ,Brian Brady resigned on June 2, 2026. Jeff Busch became interim CEO on May 31, 2026. Does Jeff even have authority to convert the debt to new shares as interim CEO because only ceo or CFO has authority to make any capital changes. An interim CEO can sign contracts on behalf of company within there authority BUT issuing new shares or converting debt requires proper corporate approvals such as board or shareholder resolutions. How did the company issue 997,160,622 new shares in the registrar without shareholder approval? This sounds like company hijacking from an unknown entity or the CEO is still running the company and didi not resigned
0 · Reply
marketmakersmarket
marketmakersmarket Jul. 4 at 4:09 AM
$ADTX Since there is no management in the company like the CFO etc how did they convert the debt to new 991,160,622 shares? Only management can access the vstock transfer account to register new shares. The ceo ,CFO says thet resigned from the govt but seems to be still in control of the company.
0 · Reply
TradeForLifeKing
TradeForLifeKing Jul. 4 at 3:58 AM
$ADTX Recent OTC stocks that ran from these levels to see below, ignore morons posting nonsense bla bla bla here, look at the mission here and it is possible to cross $5 plus soon 🔥🔥🔥🔥🔥🔥👇👇👇👇👇
2 · Reply
sullivan1
sullivan1 Jul. 4 at 3:45 AM
$ADTX $GDC So 2M can be diluted to 40M at the Max? 40M
2 · Reply
Stacked_Bands_Savage
Stacked_Bands_Savage Jul. 4 at 3:42 AM
$ADTX As I've said before. I sell nothing less than $5.
1 · Reply